At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Managing Director Russia & CIS, Janssen, pharmaceutical division of Johnson & Johnson, Director General Johnson & Johnson LLC
Started her career with Johnson & Johnson back in 2001. Throughout her 18-year career in the company, Katerina held various positions of increasing level of responsibility in sales, marketing, quality and market access departments, and consistently demonstrated integrity and strong results. Katerina has been a member of Janssen Russia board of directors since 2010 and was appointed Country Manager Russia in 2015; she was promoted to the position of Managing Director Janssen Russia & CIS in 2017. In April 2019 she was appointed Director General Johnson & Johnson LLC.
GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Every day, we help improve the health of millions of people around the world.
Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.
For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Managing Director, MSD Russia and EEU
Marwan Akar has been working as Managing Director of MSD Pharmaceuticals since 2017. In this position, he is responsible for MSD (Merck Sharp & Dohme) operations in Russia.
Mr. Akar has been with the company for more than 20 years. Prior to his appointment to Russia, he was Chief of Staff to the President of MSD Emerging Markets Region. In this position, Mr. Akar was responsible for developing and implementing the company's strategic projects in the countries of the Asia-Pacific Region (excluding China and Japan), Latin America (including Brazil), Eastern Europe, the Middle East and Africa.
Prior to this, Mr. Akar worked as Managing Director of MSD in Egypt. His work in this position resulted in increase in organizational efficiency and the growth of the company's business in key therapeutic areas.
In 2008, Mr. Akar was appointed as Head of Operations, MSD in EEMEA (the Eastern Europe, Middle East and Africa) & EUCAN (Europe and Canada). In this position, he supported strategic business development projects, and was responsible for the partner relationships with local manufacturers, including those in Russia.
Mr. Akar began his career at MSD as a production process engineer. As he progressed, Mr. Akar held various positions with increasing responsibilities, managed transfer technology projects for the production of vaccines and other drugs, and contributed to the increase of the production capacity of MSD and partner companies around the world.
Mr. Akar received his master’s degree in Chemical Engineering from the University of Maryland (USA). He also completed MBA (Master of Business Administration) program at Imperial College London.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: rare bleeding disorders, growth hormone-related disorders, and obesity. We aspire to take initiative in every of these therapeutic areas and drive the change.
Headquartered in Denmark, Novo Nordisk employs approximately 43, 200 people and markets its products in more than 170 countries. Highly technological modern insulins factory was launched as greenfield production in Kaluga region in 2015. The launch of Novo Nordisk insulin full cycle production was held in 2018.
Vice President & General Manager, Novo Nordisk Russia & Belarus
Hans Duijf has been appointed as Vice President and General Manager of Novo Nordisk in Russia and Belarus in September 2017.
Mr. Duijf has an extensive and diverse experience of working in Novo Nordisk headquarters and regional branches in Europe, South-East Asia and Latin America. Mr. Duijf began his career within Novo Nordisk more than 20 years ago in sales and marketing. Over the years Mr. Duijf proved himself as an effective manager in positions such as Marketing Director, Business development Director, General Director and Vice President.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com
Oliver Koehncke graduated from the Faculty of Political Science at the University of Economics in Budapest. He holds a master degree of international relations and Macroeconomics from the University of Potsdam – specialized in Eastern Europe. He is fluent in English, Hungarian, Russian, Ukrainian and Polish. He is passionate about long-distance swimming and military history.
Oliver Koehncke joined Boehringer Ingelheim in 1997. He began his career in the Central European branch office in Vienna. Since then he was assigned to several functions in marketing and sales in different countries. In 2007 he became a Senior Regional Business Manager with main focus on Central and Eastern Europe. In 2009 he returned to Poland, where he took over the position of General Director of Boehringer Ingelheim Poland. In the years 2017-2018 he was also the General Director in Boehringer Ingelheim Ukraine. Currently, from January 2020, he took over the position of General Director of Boehringer Ingelheim Russia.
Member of the Board of Employers’ Union of Innovating Pharmaceutical Companies INFARMA - he served as Vice President of the Management Board, Treasurer and Chairman of the Supervisory Board
Vice President of the Board of the AHK German-Polish Chamber of Commerce and Industry